PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ULTRAVIOLET THERAPY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 469 records · Page 26Linked to original sources
PubMed1981

Genetic aspects of psoriasis: mode of inheritance and action of PUVA on DNA.

The results of some family and experimental studies related to psoriasis are summarized. Complex segregation analysis of Lomholt's classical family material of psoriasis from the Faroe Islands gave clear evidence of a major locus (additive gene with a frequency of 0.07) plus a strong polygenic component (genetic heritability 0.87). An analysis of another family material showed complete linkage between the major locus for psoriasis and the HLA region. Treatment of cells with 8-methoxypsoralene plus a small dose of UVA induces monoadducts, some of which appear to remain in the DNA for at least 7 days of post-treatment incubation. These monoadducts can be activated to form DNA cross-links by a second, larger UVA dose. 8-Methoxypsoralene plus UVA-induced DNA cross-links can be modified by a repair process which involves the formation of DNA breaks. This process in not observed in XPA cells.

DNA↗
PubMed1981

Psoriasis in children: characteristics, prognosis and therapy. A review.

Based on data from literature and a study of 245 psoriatic children psoriasis in children was found to be more sensitive to psychic trauma, more often triggered by infections, more often localized to face and scalp, more often itching, and earlier present in girls than boys. An unfavourable course has often been seen in children with an early onset of psoriasis or with psoriasis located to face and trunk. Before starting therapy precipitating causes of psoriasis such as infections and psychic trauma should be eliminated--if possible. Most scales should be removed before topical therapy is started. Mainly topical therapy should be given, favourably in combinations. UVB therapy is effective, also in children, and may be given in any home. PUVA should not be used as it accelerates the ageing of the skin and is possibly carcinogenic. Methotrexate is too hepatotoxic to be used in children.

Administration, Topical↗
PubMed1981

[Oxygen multistep therapy and cancer. New perspectives in cancer immunology (author's transl)].

After discussing the relationships between efficacy of body-own defense, arterial pO2 level and manifestations of both primary tumors and metastases, correlations between immune state and oxygen transport into the entire body are described on the basis of experimental findings. As a conclusion drawn from these results, the precise treatment schedule of a tumor and metastases multistep prophylaxis utilizing immune stimulation by means of derivatives of cyano-ethyl urea and fortification of oxygen transport into tissues is given.

Aged↗
PubMed1995

Phototherapy.

This review illustrates that UVB phototherapy is not only a time-honored treatment, but also highly effective for widespread psoriasis. Treatment parameters include the frequency of irradiation, initial dose based on skin type or MED, increments of UV exposure, and maintenance schedule, according to defined protocols. UVB can be combined with adjunctive topical or systemic therapies either concomitantly or sequentially for additive effect. The use of various therapeutic modalities, including UVB phototherapy on a rotational basis, has been advocated for long-term control with reduced toxicity. UVB with emollients in an erythemogenic dosage schedule is as effective as PUVA for clearing of psoriasis in selected fair-skinned patients. Unlike PUVA, it does not involve a systemic photosensitizing drug and is relatively convenient and simple to use. UVB is the most commonly used therapy by dermatologists for widespread psoriasis that does not respond to topical therapies; it has been shown to be one of the most cost-effective therapies for widespread psoriasis.

Humans↗
PubMed1996

Antimicrobial effects of phototherapy and photochemotherapy in vivo and in vitro.

We investigated the antimicrobial effects of phototherapy and photochemotherapy in vivo and in vitro. First, Staphylococcus aureus samples were obtained using stamp agar medium from inflammatory lesions of 29 adult patients with atopic dermatitis before and after a single photochemotherapy. Therapy was oral PUVA (30 mg 8-methoxypsoralen, 8MOP plus 5J/cm2 UVA), topical PUVA (0.3% 8MOP plus 200 mJ/cm2 UVA) or UVB (80 mJ/cm2) irradiation. The number of S. aureus on the lesions was significantly reduced, even after a single treatment with all therapies. Reductions (mean +/- SD) were 69.3 +/- 26.9%, 76.3 +/- 31.3% and 83.8 +/- 18.5%, respectively. Secondly, we investigated the effect of PUVA (0.001% 8MOP plus 10, 20, 30, 40, or 50 mJ/cm2 UVA) and UVB (10, 30, 50, or 100 mJ/cm2) irradiation on the proliferation of S. aureus in vitro. PUVA and UVB treatment markedly inhibited the proliferation in a dose-dependent manner. These results seem to indicate the possibility that the antimicrobial effect of UV radiation contributes to successful photochemotherapy in patients with atopic dermatitis.

Adult↗
PubMed2002

Generalized lichen nitidus.

We report a 38-year-old man who presented with a generalized papular eruption that was clinically and histologically consistent with lichen nitidus. This patient's condition had been persistent for approximately 1 year; however, soon after assuming employment that entailed significant, regular sun exposure, the patient noted marked clearing of his lesions in sun-exposed areas. This case corroborates previous reports that suggest that generalized lichen nitidus can be successfully managed with ultraviolet light therapy.

Adult↗
PubMed1979

DNA repair synthesis in human skin exposed to ultraviolet radiation used in PUVA (psoralen and UV-A) therapy for psoriasis.

The ultraviolet radiation used for PUVA therapy stimulated DNA repair activity in normal human skin and in the uninvolved skin from psoriatic patients. The activity detected by autoradiography increased linearly with exposure time. No stimulation was observed when the UV-B component was removed from the incident radiation by filtration through glass. Therefore UV-B damage to DNA was found responsible for the activity detected following exposure to the unfiltered PUVA light source.

Autoradiography↗
PubMed2002

Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.

Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this population are not well qualified. Incidence and risk factors for second squamous cell carcinomas and basal cell carcinomas were studied in a cohort of 1380 psoralen + ultraviolet A-treated psoriasis patients prospectively followed for over 20 y; 264 had a squamous cell carcinoma and 258 a basal cell carcinoma after beginning psoralen + ultraviolet A therapy. After a first squamous cell carcinoma, the risk of a second squamous cell carcinoma was 26% at 1 y, 62% at 5 y, and 75% at 10 y. Risk increased with high psoralen + ultraviolet A exposure prior to the first squamous cell carcinoma (hazard ratio 3.32, 95% confidence interval 1.53, 7.18). Higher rates of post-first squamous cell carcinoma psoralen + ultraviolet A treatment also were associated with greater risk (hazard ratio 1.56 for every additional 10 treatments per year for patients with low pre-first squamous cell carcinoma psoralen + ultraviolet A exposure, 95% confidence interval 1.35, 1.81). Patients exposed to high levels of tar and/or ultraviolet B before a first squamous cell carcinoma were also at higher risk (hazard ratio 1.72, 95% confidence interval 1.14-2.60). Risk of a second basal cell carcinoma was 21% at 1 y, 49% at 5 y, and 61% at 10 y. There was some evidence that high exposure to psoralen + ultraviolet A before a first basal cell carcinoma was associated with increased risk of second basal cell carcinoma (hazard ratio 1.45, 95% confidence interval 0.97-2.17). Higher post-first tumor psoralen + ultraviolet A treatment rates also increased risk (hazard ratio 1.24 for every additional 10 treatments per year, 95% confidence interval 1.06-1.47). Psoralen + ultraviolet A-treated psoriasis patients appear to have a greatly increased incidence of second squamous cell carcinoma compared with the general population. Patients who develop a squamous cell carcinoma after starting psoralen + ultraviolet A therapy should be closely monitored for a subsequent squamous cell carcinoma.

Aged↗